Patients

This red chair is a reminder that patients can’t wait

Colleagues rally around a red chair as a reminder to work urgently for the people who need lifesaving medicines and vaccines

November 14, 2025

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Red chair with clock above it and shadows of patients in the background

When his close colleague’s father passed away in 2021, it was a stark reminder to Prashant Nikam: Patients can’t wait for lifesaving medicines and vaccines. Spurred by this loss, Nikam and his colleagues in Australia and New Zealand created a visual reminder of the people we’re working for: They put a red chair in their meeting room and asked, “What if the patient was sitting right here with us?” 

“Every day, someone’s relying on us. We need to make sure we’re doing everything possible so they can have access to our products in a timely manner.”

  • Prashant Nikam
    Managing director, Japan

“When we see that red chair in our workspace, when we envision that patient being in the room listening to us, we make decisions that are truly focused on doing what’s best for them,” said Nikam, now managing director, Japan.

The red chair: an urgent reminder to elevate the patient voice 

What started as a simple but powerful concept in Australia and New Zealand has now grown into a rallying cry at our sites around the world, due in part to support from Linda Kollmar, AVP of our patient innovation and engagement team. 

“People are urgently waiting for us to get our drugs and vaccines approved where they live, for access, for a prescription,” said Kollmar. “So, it’s more than just a red chair; it’s a mindset. And it transforms the way we work to ensure we’re keeping patients front and center.”  

The initiative now spans more than 40 of our global locations, where colleagues across the company have placed a chair representing the patient in boardrooms, conference rooms, labs, cafeterias and other workspaces.  

“When I’m thinking about a decision I’m making or work I’m doing, I think, ‘What if the patient was sitting right next to me? What would they be thinking and how would they want me to work with urgency for them?’”

  • Linda Kollmar
    AVP, patient innovation and engagement
Red chair in a spotlight

It’s an initiative that complements the work of her team, which engages with patients, patient advocates and communities to learn more about their perspectives, challenges and needs. The team brings that patient voice into the work we do — from discovery and clinical development to manufacturing and beyond. The chair is an additional, physical reminder to always think of the patient. 

A growing grassroots effort inspires new ways to put patients first 

Collage of red chairs in different locations including lab, conference room, lobby etc.

“As we started spreading the word about the red chair and hearing success stories from different teams, we realized that this is really a movement at a grassroots level that people can embrace to inspire them to put patients first,” Nikam said.

One of those first success stories came from the market access team in Australia, who wanted to help speed up the long approval process for a new medicine.

“Envisioning the patient in the room with them, the team brainstormed ways to highlight the urgency of the situation. They decided that in addition to bringing the safety, efficacy and economic data into their health technology assessment submissions, they would also bring the patient voice to the health authorities,” said Nikam. “So, they collected patient commentaries — inspiring and emotional stories of what it means to be a patient and without timely access to innovative medicines — and included these with our new submissions. These patient stories were overwhelmingly powerful firsthand accounts that authorities couldn’t ignore.”

A history and a future of putting patients first

This longstanding commitment to patients can be traced back to our company’s beginnings more than 130 years ago. In 1925, then-president George W. Merck said, “We try never to forget that medicine is for the people. It is not for the profits.”

That ethos continues to inspire us today. The red chair is one way we maintain our focus, but it’s a sentiment that’s important for all who serve patients to embrace.

“It’s not just for us. It’s bigger than us,” said Kollmar. “I would love to see more red chairs representing patients all over the globe. That would be incredible.”

Patients

More treatment options mean more flexibility for people with cancer

Additional treatment options can help patients make time for their health and their priorities

October 28, 2025

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

younger woman in the kitchen with her arm around an older woman and a young man nearby smiling

Every person diagnosed with cancer is unique. That’s why it’s so important for patients to have more treatment options, including ones that for some patients could be given in different care settings that are closer to home. This may give them flexibility and potentially allows them to have more time to care for their health.

Understand cancer treatment options

Advances in cancer treatment are happening every day and therapeutic options are continuously expanding. The right cancer treatment for a given patient depends on many factors including the type of cancer they have, the stage of their cancer and their overall health. Some common options include:

  • Radiation therapy
  • Chemotherapy
  • Hormone therapy
  • Targeted therapy
  • Immunotherapy
  • Surgery

Each of these types of cancer treatment work in a unique way to help treat the disease. Certain treatments also can be delivered in different ways, including but not limited to:

  • Orally: Via a pill or something taken by mouth
  • Topically: Applied to the surface of the skin
  • Intravenously: Administered through a needle or tube inserted into a vein (also called an infusion, when the medication is delivered over a specified period of time)
  • Subcutaneous injection: Via a needle inserted directly into the fatty tissue layer between the skin and muscle — or right under your skin

As additional treatment options become available, patients and caregivers are more likely to be able to consider which treatment option works best for their condition, lifestyle and preferences.

Researchers are exploring how to make treatment more flexible

Traditionally, some therapies have been administered only in hospitals and infusion clinics, often requiring patients to travel for their care, which can be time-consuming and burdensome. Once patients arrive, there are multiple steps health care providers must take in preparing for and administering treatment and observing the patient afterwards. A treatment day can be long when you consider the time from when patients leave their homes to the time they return from treatment.

Recent research has led to options that may allow for treatment to be administered subcutaneously rather than intravenously, making it possible for patients to receive treatment in more health care settings such as a doctor’s office or a community-based care center. With more choices available, patients have options that may allow them to personalize their treatment approach based on their specific lifestyle needs, so they can focus on other things that matter to them. These options may also provide additional flexibility and time savings for health care providers and systems.

Dr. M. Catherine Pietanza

“Time is one of the most valuable resources we all have, and at Merck we believe in prioritizing health so we can embrace every moment.”

  • Dr. M. Catherine Pietanza
    Vice president of global clinical development, Merck

“Cancer is not a one-size-fits-all disease, so it’s important that health care providers are able to offer treatment options that allow patients more flexibility,” said Pietanza.

Make time for your health — and the other parts of your life, too

Roz Faulhaber, a school counselor who had colorectal cancer, discovered firsthand the challenges of finding enough hours in the day to make time for everything following a cancer diagnosis.

“Receiving cancer treatment while trying to maintain a sense of normalcy in my life has been very challenging at times. I commute several hours to my treatment center and once I get there, the treatment itself can take hours. I want to spend more of my day with my grandchildren or relaxing at our beach home,” said Faulhaber.

Roz Faulhaber

“Discussing my treatment options with my doctor has been crucial — they’ve helped me select a care plan that best meets my needs, and we continue to discuss options that could give me time back in my day and flexibility.”

  • Roz Faulhaber

Patients should talk to their health care provider about treatment options, including methods of administration and dosing schedules, that fit their needs and may provide them with more flexibility.

Learn about our oncology research.

Patients

Podcast: A candid conversation about diversity in clinical trials 

Hear a patient and a doctor share why they want more people involved in medical studies

May 2, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

diversity in clinical trials

Clinical trials are an important part of helping to ensure new medicines are safe and effective. Yet a lack of awareness and feelings of hesitancy about joining one persist. 

Some people are uncertain about medical research due to past studies like the Tuskegee Experiment, when Black men were denied treatment for syphilis in the 1930s. Today, many are cautious when receiving advice from members of the medical community, including their doctors.  

Euvon Jones — a motivational artist, proud father and husband and a former clinical trial participant — hadn’t thought much about clinical trials before his diagnosis with prostate cancer, but he eventually decided to participate in a study to advance knowledge of the condition not only for himself but also for his community. 

Listen to the podcast

Read the transcript

In this podcast, Jones joined Adrelia Allen, executive director of clinical trial patient diversity at our company, and Dr. Renee Matthews, director of live programming and production at BlackDoctor.org, to share the factors that impacted his decision to participate in a clinical trial and how that experience changed his perspective on medical research.

Jones said it’s hard to trust the process if you don’t trust your health care provider or the person recommending a clinical trial. “Good information might be provided, but you have to trust that the information is good for you,” he said. 

Additionally, Matthews discussed how misinformation perpetuates stigma around clinical trials and the work that her organization is doing to help instill confidence in people who are considering participating in clinical trials.  

Patients

Podcast: How to bridge diversity gaps in cancer clinical trials

Luther Clark talks with Lazarex Cancer Foundation's Dana Dornsife and Marya Shegog about increasing access among historically underrepresented communities

May 17, 2021

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Luther Clark, Dana Dornsife and Marya Shegog

Diversity in cancer clinical trials is essential to show if potential treatments are safe and work well for people of all different communities. That’s why it’s crucial to break down barriers and increase participation in cancer clinical trials among historically underrepresented communities.

In this podcast, Luther Clark, Merck’s deputy chief patient officer, speaks with the Lazarex Cancer Foundation’s founder and CEO, Dana Dornsife, and its health equity and diversity coordinator, Marya Shegog, about the work they’ve been doing — and the work that still needs to be done — to foster health equity through cancer clinical trials.

Listen to the podcast

Read the transcript